Clinic or home: a St. Louis caregiver reads the survey

You are the one who keeps the calendar. You know which medication he quit in March, which one made her sleep fourteen hours a day, and how long it has been since anyone in the house said "better" and meant it.

So the first question a new treatment raises for you is logistical: where, how long, and who drives?

In June 2026 we paid to put a version of that question to 443 adults across ten Midwest states, and their answer is worth having in hand before you start calling clinics in St. Louis.

What people said about where they want care

Our respondents were asked where they would want ketamine or esketamine therapy delivered if it came their way. A clinic visit in person led at 44 percent. Telehealth from home got 22 percent, a hybrid that begins in the clinic and moves home once things settle got 23, and 11 percent were indifferent.

That is a majority who want a building, a staff, and a door: combined, 67 percent want the clinic outright or want it first. The numbers are final, and the shape is not subtle. If the person you care for dreads a treatment done on a laptop at the kitchen table, that instinct is the common one.

Why the location question is really a caregiver question

Supervised dosing is not a quick errand. There is check-in, the session, a monitoring period, and a ride home, because someone who has just been dosed cannot drive. Somebody has to be free for a block of a morning or afternoon, sometimes repeatedly in the early weeks.

In a metro like ours, the map sets that block. A family in Kirkwood and one in Florissant face very different mornings for the same appointment, and I-64 and I-270 can turn fifteen miles into an unknown. If treatment falls on a weekday, you are negotiating with your own employer as well as the clinic.

What else the survey says about how families choose

The first finding is money. When respondents chose the two things that matter most in a provider, insurance coverage landed on 85 percent of lists, far ahead of everything else. Nearness came second at 43 percent, which says proximity is real but secondary: people will drive if the visit is covered.

The second is the referral. Advice from their own doctor was the persuader for 74 percent, against 2 percent for an ad. If you are trying to move a reluctant spouse or parent, a website will not do it. Getting them in front of the physician they already trust will.

The distinction you cannot let anyone blur

When a clinic or telehealth service says "ketamine," ask which thing it means, because two different things share the word.

One is esketamine, sold as Spravato, which has FDA approval for depression that other medicines have not relieved. It is only administered inside certified clinics, where staff monitor the patient afterward, so by design it cannot happen at home. That structure is why the in-clinic option exists at all. To see how one program handles those visits, Brain Recovery Centers has a page on its Spravato treatment worth reading before your first call.

The other is at-home ketamine, usually a lozenge or dissolving tablet prescribed after a telehealth visit, a far grayer category. It is prescribed off label, oversight varies widely between companies, and it lacks the same approval. You need not referee that debate; just know which of the two someone is selling when they quote a price or a schedule.

A practical sequence for a St. Louis family

• Start with the primary care doctor, even if you expect a referral. That visit converts a reluctant patient and creates the documentation an insurer will want.
• Before calling any clinic, ask the insurer whether esketamine is covered and whether it runs through the medical side or the pharmacy side; that second answer tells you who to argue with after a denial.
• Ask each clinic how long the whole visit runs, door to door with monitoring, then add real drive time both ways and see whether the week can absorb it.
• Ask how often visits come in the first month. Twice a week is a different life than twice a month.
• Settle the driving before the first appointment. If you cannot drive every time, line up a second person now.

If the person you love wants the at-home route

A home-based telehealth route was what 22 percent of respondents wanted, so it is not a fringe wish. For someone with severe anxiety about leaving the house, or a job with no give, the appeal is obvious.

If that is the direction, push on the same details. Who prescribes, and are they licensed in Missouri? What screening happens before the first dose? Is anyone reachable during a session? How is the medication stored in a house that may hold teenagers or a person in crisis? What happens if it does not help?

One more thing worth saying out loud

Nearly three quarters of the people we surveyed, 72 percent, had watched ordinary prescriptions leave depression, anxiety, or PTSD unresolved somewhere in their household or close circle. If it feels like your family is the only one grinding through this, the data says otherwise. You are in the majority, sitting in a lot of parked cars outside a lot of buildings, waiting.

None of this is medical advice. Whether a given treatment fits your person is not something a survey can answer; that belongs to a clinician who knows their history, medications, and risks.

If the person you care for has talked about not wanting to be here, or that thought has started visiting you, do not sit on it. Dial or text 988, day or night; the Lifeline takes calls from worried relatives as well as from people in crisis. Asking for help on someone else's behalf is allowed.

Methodology

We commissioned this survey as the site's publisher, and we covered its cost. Pollfish ran it on its consumer panel, and before the June 23, 2026 cutoff 443 people aged 18 to 64, from a ten-state Midwest footprint that includes Missouri and Illinois, had passed a consent screen and answered. Questions that allowed more than one answer are reported as shares of respondents and sum above 100. Every figure has been through the panel's validation.